EMBRACE, the second study within the CYB003 Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia Recently cleared to initiate the EMBRACE study in Ireland, Poland, Greece, and the United Kingdom Patient dosing continues in APPROACH, the first Phase 3 study, and patient rollover into EXTEND long-term extension study is ongoing Data from... Read More

TORONTO / Aug 18, 2025 / Business Wire / Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company’s annual meeting of shareholders held on August 18,... Read More

Cybin continues to make significant progress on its journey to bring breakthrough therapies to patients by delivering on the following key milestones Received European and United Kingdom Medical and Healthcare Products Regulatory Agency (“MHRA”) approval for EMBRACE, the Company’s second pivotal study evaluating CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”) on schedule EMBRACE study to enroll 330... Read More

EMBRACE, the second study within the Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe, the United Kingdom, and Australia European CTA approval to initiate the EMBRACE study in Ireland, Poland, and Greece has been received Recently received Medicines and Healthcare products Regulatory Agency (“MHRA”) approval to commence EMBRACE in the United Kingdom... Read More

TORONTO / Aug 06, 2025 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity... Read More

EMBRACE, the second Phase 3 study within the PARADIGM program, expects to enroll 330 participants at approximately 60 clinical sites across the United States, Europe and Australia and will commence imminently PARADIGM TM comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH® and EMBRACE®) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550... Read More

Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 TORONTO / Jul 01, 2025 / Business Wire / Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing... Read More

Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 patients 1 Strengthened commercial preparations and manufacturing capabilities through partnerships with Osmind and Thermo Fisher Scientific, respectively APPROACH... Read More

Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 TORONTO / Jun 30, 2025 / Business Wire / Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing... Read More

Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder (“MDD”) with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company’s commercialization and manufacturing capabilities Positive regulatory signals from U.S. Agencies amid expanding media... Read More

TORONTO / Jun 12, 2025 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a virtual fireside chat at the H.C.... Read More

Cybin CEO Doug Drysdale to participate in a panel discussion titled “The Home Stretch: Pivotal Trials and Preparing for Launch” on June 19, 2025 TORONTO / Jun 11, 2025 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment... Read More

Newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine (“DMT”) and deuterated isotopologues for intramuscular injection, including CYB004, with expected exclusivity until 2040 Cybin’s growing intellectual property portfolio comprises more than 90 granted patents and over 230 pending applications TORONTO / Jun 03, 2025 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or... Read More

TORONTO / May 22, 2025 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a Water Tower Research Fireside Chat taking... Read More

U.S. Food and Drug Administration (“FDA”) Commissioner identifies psychedelic drug development as a top agency priority in an effort to address unmet needs in mental health Calls for FDA to be open to innovative treatments that show promise, even when they challenge traditional understanding of medicine CYB003 granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder... Read More

Thermo Fisher Scientific, the world leader in serving science, is providing Phase 3 capsule clinical supply and will support future commercial manufacturing efforts for CYB003 Production of both drug substance and drug product will be performed at Thermo Fisher’s U.S. pharma services manufacturing sites TORONTO / May 15, 2025 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a... Read More

TORONTO / May 14, 2025 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the virtual Alliance... Read More

Newly issued patent includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041 Cybin’s growing intellectual property portfolio comprises more than 80 granted patents and over 230 pending applications Patient dosing continues in APPROACH, Cybin’s first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder (“MDD”) Second Phase 3... Read More

Doug Drysdale, CEO, to appear on panel entitled “The Global Landscape and Opportunities for Medical Breakthroughs,” on May 5, 2025 TORONTO / May 01, 2025 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today... Read More

Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in 71% of MDD patients Patient dosing continues in APPROACH, Cybin’s first pivotal Phase 3 study of... Read More

Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for its clinical-stage pipeline Osmind is a leading service provider to psychiatry practices in the U.S. focused on advancing psychiatry through technology and services to bring innovative mental health treatments to patients in need TORONTO / Apr 21, 2025 / Business Wire / Cybin Inc. (NYSE... Read More

Launched strategic clinical site partnerships to accelerate PARADIGM, a multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder (“MDD”) PARADIGM comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 patients APPROACH has... Read More

Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve overall site performance First program member is Segal Trials, a preferred provider for leading pharmaceutical companies globally Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12... Read More

Announced positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder (“MDD”) Initiated PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of MDD Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003 for the Adjunctive Treatment of MDD Topline efficacy data from Phase 2... Read More

TORONTO / Jan 09, 2025 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Lytham Partners 2025... Read More

Poster presentations highlight clinical data across Cybin’s CYB003 deuterated psilocin and DMT programs TORONTO / Dec 10, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the presentation of... Read More

TORONTO / Dec 04, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, and Amir Inamdar, MBBS, DNB (Psych), FFPM, Cybin’s Chief... Read More

100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale (“MADRS”) score compared to baseline at 12 months after two 16 mg doses of CYB003 Findings validate dosing regimen and confirm that CYB003’s effects are highly durable and offer sustained... Read More

Company to host conference call and webcast at 8:00 a.m. ET on Monday, November 18, 2024 Presentation will also include discussion of its recently initiated Phase 3 PARADIGM program for CYB003 TORONTO / Nov 14, 2024 / Business Wire / Cybin Inc . (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by... Read More

PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) APPROACH ™: A P hase III, P lacebo-Controlled, R andomized, Double-Blind Trial of O ral Doses of CYB003 to A ssess C ombined Safety and Efficacy in H umans with Major Depressive... Read More

CEO Doug Drysdale to speak on panel about novel approaches to mental health treatments on November 13, 2024 TORONTO / Oct 31, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that... Read More

The Company is evaluating non-hallucinogenic dosing of CYB005 preclinical candidate molecules for the treatment of CNS disorders Cybin’s sector-leading intellectual property portfolio now includes over 70 granted patents and more than 220 patent applications pending TORONTO / Oct 24, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough... Read More

TORONTO / Oct 03, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in the Water Tower Research Fireside Chat... Read More

Company is on track to initiate its global Phase 3 pivotal program for CYB003 in Major Depressive Disorder (“MDD”) imminently Cybin welcomes Dr. Mirza Rahman as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo Gutierrez as Vice President, Clinical Pharmacology Other recent additions to the team include project directors. project managers, and clinical monitoring managers, as well as previously... Read More

TORONTO / Sep 24, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Amir Inamdar, Cybin’s Chief Medical Officer, will participate in a panel discussion at the TD Cowen 4th Annual... Read More

Initiation of pivotal CYB003 Phase 3 study in Major Depressive Disorder (“MDD”) expected imminently 12-month efficacy data from Phase 2 study of CYB003 in MDD expected in early Q4 2024 Phase 2 topline efficacy and safety results for CYB004 in Generalized Anxiety Disorder (“GAD”) expected year-end 2024 or early Q1 2025 Strengthened R&D team with addition of experienced drug development leaders Dr. Atul R. Mahableshwarkar, and... Read More

TORONTO / Sep 19, 2024 / Business Wire / Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that it has filed articles of amendment to consolidate the Company’s issued and outstanding common shares (the “... Read More

TORONTO / Sep 04, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat and panel at the H.C.... Read More

TORONTO / Aug 27, 2024 / Business Wire / Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) ( Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders... Read More

Company expects to initiate Phase 3 pivotal trial in late summer 2024 Phase 3 pivotal study to include 30 clinical sites across the United States and Europe with deep expertise in depression studies Pivotal trial designs incorporate elements to address functional unblinding Company to report 12-month Phase 2 efficacy data for CYB003 in Major Depressive Disorder (“MDD”) in Q4 2024 TORONTO / Aug 13, 2024 / Business Wire /... Read More

Phase 3 multinational study of CYB003 expected to begin in late summer 2024 30 clinical sites selected across the United States and Europe for Phase 3 CYB003 study 12-month efficacy results from Phase 2 study of CYB003 in MDD expected Q4 2024 Additional United States patent granted providing protection for the CYB004 program Strengthened R&D team with additional experienced drug development leaders Cash totaled C$183 million... Read More

TORONTO / Aug 07, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity... Read More

Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”) Clinical site selection complete for Phase 3 multinational study of CYB003, which is expected to begin in summer 2024 Cash totaled C$209 million as of March 31, 2024 Initiated a Phase 2 study of... Read More

TORONTO / Jun 19, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 5th... Read More

Dr. Mahableshwarkar, a Board-Certified Psychiatrist, is an experienced pharmaceutical industry leader with decades of expertise in drug development TORONTO / Jun 11, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based... Read More

Amir Inamdar, Chief Medical Officer, to appear on panel discussions on June 5 and June 8 - Ellen James, Director, Clinical Development, to present abstract titled “SPL026 (DMT fumarate) in combination with SSRIs for patients with Major Depressive Disorder” on June 6, 2024 TORONTO / May 29, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical... Read More

TORONTO / May 14, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the virtual Alliance... Read More

Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports advancement of clinical-stage programs CYB003 and CYB004 Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, a proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”) Initiation of pivotal... Read More

Doug Drysdale, CEO, to appear on panel entitled “Collaborating for Improved Mental Health,” on May 8, 2024 TORONTO / Apr 25, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Doug... Read More

- Publication explores structure-activity relationships (“SAR”) of a broad range of 2C-X analogs - - Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT 2 receptor agonist with favorable pharmacokinetic properties - TORONTO / Apr 18, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company... Read More

Newly issued patent expected to provide exclusivity until at least 2041 and includes claims to pharmaceutical compositions within the Company’s proprietary deuterated psilocybin analog program Cybin’s patent portfolio now includes more than 50 granted patents and over 170 pending applications Company expects to commence enrollment for a multinational, multisite Phase 3 program evaluating CYB003 in Major Depressive Disorder... Read More

TORONTO / Apr 10, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the 2024 Bloom Burton & Co. Healthcare... Read More

TORONTO / Mar 19, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce the closing of the Company’s previously announced private placement (the “ Private Placement ”) of... Read More

TORONTO / Mar 18, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 in Dallas, TX. Doug Drysdale, Chief... Read More

Anxiety disorders are the most prevalent mental health disorders globally 1 , contributing to over 28 million disability-adjusted life years (“DALYs”) 2 Highly scalable intermittent treatment for Generalized Anxiety Disorder (“GAD”) with an expected treatment time of approximately 90-minutes from a single administration Proprietary deuterated dimethyltryptamine (“DMT”) molecule with U.S. composition of matter patent granted... Read More

With U.S. Food and Drug Administration (“FDA”) alignment on multisite, multinational Phase 3 program design Company expects to commence Phase 3 program around mid-year 2024 15 U.S. clinical trials sites targeted; European sites to be added Robust and sustained improvement in depression symptoms with CYB003 at four months with 75% of patients in remission from depression after two doses (16mg) Breakthrough Therapy Designation... Read More

TORONTO / Mar 13, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce a proposed private placement (the “ Private Placement ”) of 348,837,210 common shares in the capital of the... Read More

Breakthrough Therapy Designation (“BTD”) provides an expedited review pathway, as well as increased access to U.S. Food and Drug Administration (“FDA”) guidance on trial design, with the potential to significantly reduce drug development timelines First known BTD granted by the FDA for an adjunctive psychedelic based therapy... Read More

Program update includes 4-month durability data from Phase 2 trial of CYB003 in Major Depressive Disorder (“MDD”) Company speakers include Doug Drysdale, Chief Executive Officer and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer TORONTO / Mar 12, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to... Read More

TORONTO / Feb 27, 2024 / Business Wire / Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the TD Cowen 44 th Annual Health Care... Read More

Reported positive Phase 2 topline results for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”), demonstrating a 79% remission rate from depression Announced positive topline results from Phase 1 studies of proprietary deuterated dimethyltryptamine (“dDMT”) molecules CYB004 and SPL028, supporting clinical advancement and the successful... Read More

Newly issued patents include protection for injectable formulations and synthesis methods for the preparation of dimethyltryptamine (“DMT”) and deuterated DMT (“dDMT”) Patent protection further strengthens intellectual property portfolio in the 3 rd largest pharmaceutical market globally Cybin’s patent portfolio now includes 51 granted patents and over 170 pending applications TORONTO / Feb 07, 2024 / Business Wire / Cybin... Read More

Recently announced positive Phase 1 topline safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data show that intravenous (“IV”) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT U.S. composition of matter patent granted with protection expected through 2041 Company to initiate a randomized, double-blind, active controlled Phase 2a study in Q1 2024 TORONTO / Jan 23,... Read More

Intravenous (“IV”) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment Intramuscular (“IM”) dosing of SPL028 produced robust, short-duration psychedelic effects in the majority of participants Both IV and IM routes were safe and well-tolerated, with potential for IM administration to provide more convenient,... Read More

Recently announced positive Phase 2 topline data in Major Depressive Disorder (“MDD”) with 79% of patients in remission from depression after two doses of CYB003 (12mg) Programs supported by robust intellectual property portfolio with 40 granted patents and over 170 pending applications Multinational operations support scaling to Phase 3 trial of CYB003 in MDD and Phase 2 study of deuterated dimethyltryptamine (“dDMT”) in... Read More

Newly issued patent expected to provide protection until at least 2041 and includes composition of matter claims to pharmaceutical compositions within the Company’s proprietary CYB003 deuterated psilocybin analog program Cybin’s patent portfolio now includes 39 granted patents and over 170 pending applications Recently announced positive topline data from Phase 2 study of CYB003 in major depressive disorder showed 79% of... Read More

Poster presentations highlight data across Cybin’s CYB003 and deuterated DMT clinical programs, as well as preclinical development programs TORONTO / Dec 05, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment... Read More

Rapid, robust, and clinically significant reduction of depression symptoms observed after a single dose of CYB003, with a clear incremental benefit of a second dose Primary efficacy endpoint achieved with an impressive mean -14 point difference in Montgomery-Asberg Depression Rating Scale (“MADRS”) score reduction from... Read More

Company speakers include Doug Drysdale, Chief Executive Officer; and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer Featured key opinion leaders include Dr. Maurizio Fava, M.D., Massachusetts General Hospital and Harvard Medical School; and Dr. Gitte Moos Knudsen, Professor, Chief Neurologist, DMSc, Neurobiology Research Unit, Rigshospitalet and University of Copenhagen, Denmark Topics include topline Phase 2... Read More

Company to share topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder TORONTO / Nov 16, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next generation... Read More

TORONTO / Nov 15, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced a poster presentation at Neuroscience 2023 hosted by the Society for Neuroscience (“SFN”) taking place November 11-15,... Read More

Announced unprecedented positive Phase 2 interim data for CYB003, its proprietary deuterated psilocybin analog, in major depressive disorder Announced closing of a unit offering of up to US$64 (C$88.4) million led by one of its largest institutional shareholders Strengthened patent portfolio with the addition of four new patents Completed acquisition of Small Pharma Inc. Topline clinical readout of Phase 2 efficacy data for... Read More

TORONTO / Nov 14, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that it has closed its previously announced underwritten offering (the “ Offering ”). In connection with the Offering,... Read More

TORONTO / Nov 10, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce a firm commitment underwritten offering (the “ Offering ”) of 66,666,667 units of the Company (the “ Units ”) to one of... Read More

CEO Doug Drysdale to speak on panel about innovations in mental health care on November 7, 2023 TORONTO / Nov 03, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive... Read More

Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) For reference, pooled data... Read More

Company to host conference call to discuss positive Phase 2 CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET Complete Phase 2 topline data for CYB003 in MDD expected in Q4 2023 TORONTO / Nov 01, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and... Read More

Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) For reference, pooled data... Read More

Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale (“MADRS”) score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) For reference, pooled data... Read More

European patent provides composition of matter and medical use protection for the Company’s proprietary deuterated psilocybin analog and deuterated DMT programs New European patent further strengthens intellectual property portfolio, which now includes 33 granted patents and over 170 pending applications TORONTO / Oct 26, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a... Read More

New United States patent grants offer protection for deuterated analogs of DMT including composition of matter, medical use and synthesis Intellectual Property portfolio provides robust protection for most extensive deuterated DMT portfolio in the sector Cybin’s Intellectual Property portfolio now consists of 32 granted patents and over 170 pending applications TORONTO / Oct 25, 2023 / Business Wire / Cybin Inc. (NYSE... Read More

Combined portfolios create the industry’s largest, most advanced, well-protected deuterated DMT program Combination creates the largest intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy TORONTO & LONDON / Oct 23,... Read More

LONDON & TORONTO / Oct 17, 2023 / Business Wire / Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (“ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions and Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based... Read More

TORONTO / Oct 12, 2023 / Business Wire / Cybin Inc. (NYSE AMERICAN:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on October... Read More

Abstract entitled, “Structure-activity of 2C-X psychedelics to develop a novel 5-HT 2A receptor full agonist with therapeutic potential” Highlights preclinical work done to support selection of a development candidate for the Company’s phenethylamine program Cybin to moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit titled “Making Psychedelic Clinical Trials a Reality: Mitigating... Read More

TORONTO / Oct 04, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the Jefferies Inaugural Biotech CNS/Neuro Summit, taking... Read More

Topline efficacy data expected in Q4 2023 Preparations are underway to scale the CYB003 program to a potential Phase 3 study in early 2024 TORONTO / Oct 03, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today... Read More

TORONTO / Sep 26, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced an agreement with Fluence, a leading continuing education organization in psychedelic therapy, to support the streamlining and scaling... Read More

TORONTO / Sep 25, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Chief Executive Officer of Cybin, and George Tziras, Chief Executive Officer of Small Pharma Inc., will... Read More

TORONTO / Sep 21, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its 2023 Annual and Special Meeting of Shareholders will be held virtually on Thursday, October 12, 2023 at 1:00 p.m. ET. The... Read More

Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2 data for pivotal studies Breakthrough Therapy designation anticipated in late 2023, subject to FDA approval Previously announced acquisition of Small Pharma Inc. expected to close in Q4 2023, creating an international clinical-stage leader in novel psychedelic therapeutics... Read More

Newly granted U.S. patent further strengthens the Company’s leadership position in the deuterated tryptamine space - With the recently announced definitive agreement to acquire Small Pharma Inc. The granted patent will add to the most impressive intellectual property portfolio in the psychedelic drug development sector with 29 patents granted and over 150 patents pending TORONTO / Sep 05, 2023 / Business Wire / Cybin Inc.... Read More

All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy Combined portfolio creates the industry’s largest, most advanced, well-protected deuterated DMT program Combination creates the largest intellectual property portfolio in the psychedelic drug... Read More

TORONTO / Aug 23, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today that it has renewed its previously established at-the-market equity program (the “ ATM Program ”) that allows Cybin to issue and sell up... Read More

CYB003 capsule formulation is designed to be stable, dose flexible, patient-friendly and commercially scalable Shipments of CYB003 capsules to clinical sites expected in Q1 2024 Recently granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 TORONTO / Aug 17, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “... Read More

Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 Company’s intellectual property portfolio now encompasses 2 granted U.S. patents, and over 50 pending patent applications across 6 patent families TORONTO / Aug 15, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage... Read More

Topline clinical data readouts expected in Q3/Q4 2023, including Phase 2 efficacy data for CYB003 and Phase 1 data for CYB004 U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2a data for end of Phase 2 meeting expected in Q4 2023 Preparations underway for pivotal studies, including the development of a scalable psychedelic facilitation training program, EMBARK CT , and partnership with Worldwide... Read More

TORONTO / Aug 04, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has closed its previously announced overnight marketed public offering (the “ Offering ”). In connection with the... Read More

To date, CYB003 has demonstrated a robust psychedelic response and a favorable safety and tolerability profile at doses of up to 12mg Phase 2 topline efficacy data expected in Q3/Q4 2023 TORONTO / Aug 02, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative... Read More

TORONTO / Aug 01, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today the pricing of its previously announced overnight marketed public offering (the “ Offering ”) of an aggregate of 24,264,706 units of the... Read More

TORONTO / Jul 31, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has launched an overnight marketed public offering of units of the Company (the “ Units ”) at a price per Unit and for... Read More

TORONTO / Jul 27, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 43 rd Annual... Read More

Collaboration with Worldwide Clinical Trials provides Cybin with access to a contract research organization with substantial experience supporting multinational psychedelic clinical trials Cybin expects to report Phase 2 topline efficacy data for CYB003 in major depressive disorder in Q3/Q4 2023 TORONTO / Jul 26, 2023 / Business Wire / Cybin Inc . (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ”), a clinical-stage... Read More

Cohort 5 completed with no safety or tolerability issues, Final cohort 6 is recruiting with dosing expected to commence shortly Phase 2 efficacy data for CYB003 in major depressive disorder expected in Q3/Q4 2023 U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2a data for pivotal studies expected following topline efficacy data readout TORONTO / Jul 24, 2023 / Business Wire / Cybin Inc. (NYSE... Read More

TORONTO / Jul 20, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, commends Kernel, a leader in non-invasive neuroimaging, on their publication titled " Measuring acute effects of subanesthetic ketamine on... Read More

LOS ANGELES / Jul 20, 2023 / Business Wire / Kernel, a leader in non-invasive neuroimaging, announces the publication of their study " Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS ," in the journal Scientific Reports from the Nature Portfolio of Journals. The study, sponsored by Cybin Inc . (NEO:CYBN) (NYSE American:CYBN), underscores the ability of Kernel’s Flow1... Read More

EMBARK for Clinical Trials (“EMBARK CT ”) being developed as a scalable model of psychedelic facilitation training to support future pivotal studies American Medical Association (“AMA”)’s new CPT codes will support potential reimbursement of in-person monitoring and support provided during psychedelic treatment TORONTO / Jul 12, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”),... Read More

Cybin’s Chief Medical Officer Amir Inamdar to participate in a fireside chat on July 6, 2023 TORONTO / Jun 30, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Amir Inamdar, MBBS, DNB... Read More

TORONTO / Jun 29, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce the appointment of Aaron Bartlone as Chief Operating Officer of Cybin Inc., effective July 1, 2023. Mr. Bartlone has served as... Read More

Initiated First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial Topline clinical data readouts expected in Q3/Q4 2023, including Phase 2a efficacy data for CYB003 and Phase 1 data for CYB004 1,2 U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2a data for end of phase 2 meeting expected in Q4 2023 1,2 This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus... Read More

TORONTO / Jun 27, 2023 / Business Wire / Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Mr. Sanford R. Climan has joined Cybin as a strategic advisor. Mr. Climan is the CEO and founder of Entertainment Media... Read More

TORONTO / Jun 21, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, and Allison House-Gecewicz, Cybin’s SVP of Clinical Operations, will be... Read More

TORONTO / Jun 15, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual... Read More

C$70M in potential funding through a combination of the previously announced common share purchase agreement and current “at-the-market” equity program helps support upcoming clinical milestones Topline clinical data readouts expected in late Q3 2023, including Phase 2a efficacy data for CYB003 and Phase 1 data for CYB004 TORONTO / Jun 08, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “... Read More

Michael Palfreyman Ph.D. and Brett Greene, who joined Cybin as part of the acquisition of Adelia Therapeutics, move into advisory roles Alex Nivorozhkin Ph.D. continues as Chief Scientific Officer TORONTO / Jun 05, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and... Read More

TORONTO / Jun 01, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the Jefferies Healthcare Conference taking place in New York... Read More

Share purchase agreement further strengthens Company’s position to deliver on value-driving clinical milestones TORONTO / May 30, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has entered... Read More

CYB004, a deuterated dimethyltryptamine (“dDMT”) molecule, has potential to overcome existing limitations of DMT and is protected by a composition of matter patent through 2041 Parts A and B of Phase 1 study complete; Part C to determine safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) of escalating doses of CYB004 in healthy volunteers Phase 1 topline safety and efficacy data expected in Q3 2023 TORONTO / May 24,... Read More

Advancing to first-in-human dosing of CYB004, a proprietary deuterated DMT molecule CYB004 being developed to provide less invasive and more convenient dosing methods as compared with IV infused DMT Phase 1 topline data expected in Q3 2023 TORONTO / May 09, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing... Read More

CEO Doug Drysdale to speak on a mental health panel on May 2, 2023 TORONTO / Apr 28, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking... Read More

TORONTO / Apr 12, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced the launch of EMBARK Open Access (“EMBARK OA”), a free online foundational training course for psychedelic facilitation. EMBARK OA is... Read More

TORONTO / Mar 08, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference taking place on March 13-15, 2023. Mr. Drysdale’s... Read More

TORONTO / Mar 02, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® and The Chopra Foundation, a not-for-profit organization dedicated to improving health and well-being founded by Dr. Deepak Chopra, are pleased to announce that Dr. Chopra and Chief Executive Officer of Cybin, Doug Drysdale will... Read More

TORONTO / Feb 28, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced significant progress updates for its two lead clinical development programs: CYB003, its proprietary deuterated psilocybin analog for the potential treatment of Major Depressive Disorder and CYB004, its proprietary... Read More

TORONTO / Feb 22, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced a streamlining plan aimed at maximizing the Company’s operating efficiency and to allow the Company to focus on critical clinical trials. Based on anticipated cost savings from the streamlining exercise and the... Read More

TORONTO / Feb 14, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today reported unaudited financial results for its third quarter ended December 31, 2022, and recent business highlights. “Looking ahead, we remain well-positioned to deliver on multiple near-term clinical milestones and data... Read More

Marks first ever trial to evaluate deuterated DMT in humans Based on preclinical studies CYB004 demonstrated superior bioavailability compared to IV DMT which may support less invasive dosing methods CYB004 is a patented proprietary molecule protected through 2041 TORONTO / Feb 01, 2023 / Business Wire / - Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on... Read More

TORONTO / Jan 26, 2023 / Business Wire / Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced that it will host a virtual R&D Day on Tuesday, February 28, 2023, from 10:00 a.m. ET to 11:30 a.m. ET. The event, which will be hosted by Cybin’s leadership team, will provide a progress update on the Company’s... Read More

Study supports earlier findings and demonstrates that Kernel Flow provides a functional measure of blood oxygenation changes in the brain associated with neural activity Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced key highlights from the completed feasibility study conducted by its partner HI, LLC dba... Read More

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biotechnology company focused on progressing Psychedelics to Therapeutics ® today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule, CYB004. "Based on preclinical data, CYB004 has shown... Read More

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today outlined its upcoming priorities and near-term milestones that support the development of its CYB003 and CYB004 clinical programs aimed at addressing multiple mental health conditions. “Cybin enters 2023 with the potential to reach a number of value-driving milestones,... Read More

New findings underscore potential of CYB003 as a novel psychedelic-based therapeutic for the treatment of depression TORONTO--( BUSINESS WIRE )- Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today announced that the Company presented two posters on its deuterated psilocybin analog, CYB003, at the American College of... Read More

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® , today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience (“SFN”) taking place November 12-16, 2022, in San Diego, CA. “It is exciting to be part... Read More